AN2 Therapeutics, Inc. (ANTX)

AN2 Therapeutics, Inc. (ANTX) Healthcare & Pipeline Overview

AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to addressing unmet needs in rare and serious infectious diseases. Their primary focus is the development of epetraborole, an oral treatment for chronic non-tuberculous mycobacterial lung disease, positioning them within a niche but critical segment of the healthcare market.

What Is the Investment Thesis for ANTX?

AN2 Therapeutics presents a focused investment opportunity within the biotechnology sector, primarily driven by the potential of epetraborole in treating chronic NTM lung disease. The increasing prevalence of NTM and the limitations of current therapies create a substantial market opportunity for a more effective and convenient oral treatment. Key value drivers include successful completion of ongoing clinical trials, regulatory approval of epetraborole, and subsequent commercialization. The company's market capitalization of $120.71M reflects the inherent risks associated with clinical-stage biopharmaceutical companies, including clinical trial outcomes and regulatory hurdles. A beta of -0.03 suggests a low correlation with overall market movements. The absence of a dividend reflects the company's focus on reinvesting capital into research and development. Upcoming clinical trial results for epetraborole will be a critical catalyst. Potential risks include clinical trial failures, regulatory delays, and competition from existing or emerging therapies.

Based on FMP financials and quantitative analysis

ANTX Key Highlights

• AN2 Therapeutics is a clinical-stage biopharmaceutical company focused on rare infectious diseases.
• The company's lead product, epetraborole, targets chronic non-tuberculous mycobacterial (NTM) lung disease.
• Epetraborole is designed as a once-daily oral treatment, offering a more convenient alternative to existing therapies.
• The company is headquartered in Menlo Park, California, a hub for biotechnology innovation.
• AN2 Therapeutics has a market capitalization of $120.71M, reflecting its growth potential and associated risks.

Who Are ANTX's Competitors?

ANTX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ANTX's Key Strengths?

• Focus on a specific unmet medical need in NTM lung disease.
• Oral formulation of epetraborole offers convenience over existing treatments.
• Experienced management team with expertise in infectious diseases.
• Strong intellectual property protection for its lead product candidate.

What Are ANTX's Weaknesses?

• Limited financial resources as a clinical-stage company.
• Dependence on the success of a single product candidate.
• Small team size may limit operational capacity.
• Lack of established commercial infrastructure.

What Could Drive ANTX Stock Higher?

• Results from ongoing clinical trials of epetraborole.
• Potential regulatory submissions for epetraborole.
• Progress in securing strategic partnerships and licensing agreements.
• Expansion of epetraborole's indications to other mycobacterial infections.

What Are the Key Risks for ANTX?

• Negative return on equity (-52.3%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or regulatory delays.
• Competition from existing or emerging therapies.
• Changes in the regulatory landscape for drug approvals.
• Difficulty in securing funding for ongoing research and development.
• Dependence on the success of a single product candidate.

What Are the Growth Opportunities for ANTX?

• Expansion of Epetraborole's Indications: AN2 Therapeutics has the opportunity to expand the use of epetraborole beyond chronic NTM lung disease. The drug's mechanism of action may be applicable to other mycobacterial infections or related conditions. Successful clinical trials in these additional indications could significantly increase the market potential for epetraborole. The timeline for this expansion would depend on the progress of clinical trials and regulatory approvals, potentially adding substantial value within 3-5 years. The market size for related mycobacterial infections could add several hundred million dollars to the potential revenue.
• Strategic Partnerships and Licensing Agreements: AN2 Therapeutics can pursue strategic partnerships and licensing agreements to accelerate the development and commercialization of epetraborole. Partnering with larger pharmaceutical companies could provide access to additional resources, expertise, and distribution networks. These partnerships could also help to mitigate the financial risks associated with drug development. The timeline for securing such partnerships is variable, but could lead to significant value creation within 1-2 years. The financial impact of these agreements could range from upfront payments to milestone payments and royalties on future sales.
• Geographic Expansion: AN2 Therapeutics has the opportunity to expand its geographic reach beyond the United States. NTM lung disease is a global health problem, and there is a need for effective treatments in many countries. Obtaining regulatory approvals and commercializing epetraborole in Europe, Asia, and other regions could significantly increase the company's revenue potential. The timeline for geographic expansion would depend on regulatory requirements and market access strategies, potentially contributing to revenue growth within 2-4 years. The global market for NTM lung disease treatments is estimated to be worth several billion dollars.
• Development of a Pipeline of Novel Anti-Infectives: AN2 Therapeutics can leverage its expertise in infectious diseases to develop a pipeline of novel anti-infective therapies. This could involve identifying new drug targets, developing new drug candidates, and conducting preclinical and clinical studies. A diversified pipeline would reduce the company's reliance on epetraborole and increase its long-term growth potential. The timeline for developing a pipeline of novel anti-infectives is long-term, potentially requiring 5-10 years to bring new products to market. The market for anti-infective therapies is substantial, with significant unmet needs in areas such as antibiotic-resistant infections.
• Leveraging Real-World Evidence and Data Analytics: AN2 Therapeutics can leverage real-world evidence (RWE) and data analytics to improve the diagnosis, treatment, and management of NTM lung disease. This could involve collecting and analyzing data from electronic health records, claims databases, and other sources to identify patterns, trends, and best practices. RWE can be used to support regulatory submissions, inform clinical trial design, and improve patient outcomes. The timeline for implementing RWE and data analytics is ongoing, with potential benefits realized within 1-3 years. The use of RWE could lead to more efficient clinical trials, improved patient outcomes, and increased adoption of epetraborole.

What Opportunities Does ANTX Have?

• Expansion of epetraborole's indications to other mycobacterial infections.
• Strategic partnerships with larger pharmaceutical companies.
• Geographic expansion to markets outside the United States.
• Development of a pipeline of novel anti-infective therapies.

What Threats Does ANTX Face?

• Clinical trial failures or regulatory delays.
• Competition from existing or emerging therapies.
• Changes in the regulatory landscape for drug approvals.
• Difficulty in securing funding for ongoing research and development.

What Are ANTX's Competitive Advantages?

• Patent protection for its lead product candidate, epetraborole.
• Specialized expertise in developing treatments for rare infectious diseases.
• First-mover advantage in the NTM lung disease market with an oral treatment.
• Strong relationships with key opinion leaders in the infectious disease field.

What Does ANTX Do?

AN2 Therapeutics, Inc., incorporated in 2017 and headquartered in Menlo Park, California, is a biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases. The company's lead product candidate, epetraborole, is a once-daily oral treatment being developed for patients with chronic non-tuberculous mycobacterial (NTM) lung disease, a debilitating condition with limited treatment options. AN2 Therapeutics aims to provide a more convenient and effective therapy for this patient population. The company is currently focused on advancing epetraborole through clinical development, with the goal of obtaining regulatory approval and commercializing the product. Given the increasing prevalence of NTM lung disease and the challenges associated with existing treatments, AN2 Therapeutics is positioned to address a significant unmet medical need. The company’s strategy involves leveraging its expertise in infectious diseases and drug development to bring innovative therapies to market, improving the lives of patients affected by these conditions. With a team of 22 employees, AN2 Therapeutics is structured to efficiently manage its clinical programs and advance its pipeline.

What Products and Services Does ANTX Offer?

• Develops treatments for rare, chronic, and serious infectious diseases.
• Focuses on therapies for conditions with limited treatment options.
• Creates oral treatments for patient convenience.
• Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
• Seeks regulatory approval from health authorities for its products.
• Aims to commercialize its approved therapies to reach patients in need.
• Specializes in addressing unmet medical needs in the infectious disease market.

How Does ANTX Make Money?

• Develops and patents novel pharmaceutical products.
• Conducts clinical trials to demonstrate efficacy and safety.
• Seeks regulatory approval for commercialization.
• May partner with larger pharmaceutical companies for distribution and marketing.

What Industry Does ANTX Operate In?

AN2 Therapeutics operates within the biotechnology industry, specifically targeting the infectious disease market. The biotechnology industry is characterized by high research and development costs, lengthy regulatory approval processes, and significant market potential for successful products. The infectious disease market is driven by factors such as increasing antibiotic resistance, emerging pathogens, and the growing prevalence of chronic infections. AN2 Therapeutics' focus on rare and serious infectious diseases positions it within a niche segment of the market, where unmet medical needs are significant and competition may be limited. The company's success depends on its ability to navigate the complex regulatory landscape and effectively commercialize its products.

Who Are ANTX's Key Customers?

• Patients suffering from rare, chronic, and serious infectious diseases.
• Healthcare providers who treat these patients.
• Hospitals and clinics that provide specialized care.
• Pharmaceutical distributors and pharmacies.

How AN2 Therapeutics, Inc. Is Valued

AN2 Therapeutics, Inc. carries a market capitalization of $120.71M, placing it in the micro-cap category. Relative to its peer group, ANTX's quantitative score of 58/100 is below the peer average of 76/100.

Company Profile

AN2 Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Menlo Park, US. The company is led by CEO Eric E. Easom. ANTX has traded publicly since 2022.

ROE -52%Key Financial Metrics

Return on equity for AN2 Therapeutics, Inc. stands at -52.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -39.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -26.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 15.73 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -23.8%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 2/9Financial Health

AN2 Therapeutics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 8.43 places it in the safe zone, indicating low near-term bankruptcy risk.

FY2026 estForward Outlook

Wall Street analysts project AN2 Therapeutics, Inc. revenue of about $72.7M for fiscal 2026, with EPS near $-0.96.

ANTX Financials

ANTX Latest News

ANTX Analyst Consensus

ANTX MoonshotScore

What Investors Ask About AN2 Therapeutics, Inc. (ANTX) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources